All In MedTech

Device Trial Radar · NCT07910721

Continuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic Foot.

Prevention of Diabetic Foot Ulcers Through Self-monitoring: a Performance Evaluation Study (DIAFOOTEM)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 10, 2026

Primary completion

Apr 10, 2027

Study completion Apr 10, 2027

Sponsor

Lead sponsor
SolsiusNot on our public-company list
Sponsor type
Industry
First posted
Nov 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the performance of a self-monitoring system (Solsius SelfCare) to detect pre-ulcerative clinical abnormalities in adults living with type 1 or 2 diabetes at high podiatric risk (grade 3 according to French HAS guidelines) and a history of healed diabetic foot wound. The main question it aims to answer is: \- Can the Solsius SelfCare system detect pre-ulcerative foot abnormalities with a sensitivity of at least 80%, defined as the proportion of temperature threshold exceedances (≥ 2.2°C difference between symmetric plantar sites over 2 consecutive days) confirmed by a clinical abnormality identified by a podiatrist? There is no comparison group. All participants will use the same device throughout the study. Participants will: * Wear the Solsius SelfCare connected insoles daily (except during sleep) for 12 months * Receive a push notification on their smartphone if a temperature difference ≥ 2.2°C is detected between symmetric sites on both feet over 2 consecutive days * Attend scheduled podiatric follow-up visits every 3 months (at M3, M6, M9, and M12) * Attend an additional unscheduled podiatric visit within 24 hours after each temperature alert, to verify the presence or absence of a pre-ulcerative clinical abnormality * Complete a self-questionnaire after each temperature alert and a usability questionnaire (System Usability Scale) at the end of the study

Conditions

  • Diabetic Foot Disease
  • Diabetic Foot Infection
  • Diabetic Foot Infections
  • Diabete Type 1
  • Diabetes (DM)
  • Foot

Interventions

  • Solsius SelfCareDevice

    Smart insoles incorporating plantar temperature sensors (bilateral measurement), worn daily whilst awake for 12 months. Push notification if the temperature difference between two symmetrical sites is ≥ 2.2°C for two consecutive days. Class I medical device, CE marked in accordance with MDR 2017/745.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the performance of a self-monitoring system for detecting pre-ulcerative lesions in people living with stage 3 diabetic foot disease.Time frame: 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Saint-Vincent de Paul [GHICL]

    Lille, France · Recruiting

  • CHU de Lille

    Lille, France · Recruiting

  • CHU de Montpellier

    Montpellier, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.